Skip to main content
Erschienen in: Pathology & Oncology Research 4/2020

06.07.2020 | Original Article

Concordance Between Biopsy and Radical Prostatectomy Gleason Scores: Evaluation of Determinants in a Large-Scale Study of Patients Undergoing RARP in Belgium

verfasst von: C. Soenens, P. Dekuyper, G. De Coster, N. Van Damme, E. Van Eycken, T. Quackels, T. Roumeguère, B. Van Cleynenbreugel, S. Joniau, F. Ameye, for the Be-RALP registry

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

To determine whether Gleason scores were concordant between prostate biopsies (bGS) and the definitive resection specimen (pGS) excised with robot-assisted radical prostatectomy (RARP); to identify clinical and pathological factors that might predict upgrading; and to evaluate how upgrading affected outcome. Between 2009 and 2016, 25 Belgian centers participated in collecting prospective data for patients that underwent RARP. We analyzed the concordance rate between the bGS and the pGS in 8021 patients with kappa statistics, and we compared concordance rates from different centers. We assessed the effect of several clinical and pathological factors on the concordance rate with logistic regression analysis. The concordance rate for the entire population was 62.9%. Upgrading from bGS to pGS occurred in 27.3% of patients. The number of biopsies was significantly associated with concordance. Older age (>60 y), a higher clinical T stage (≥cT2), a higher PSA value at the time of biopsy (>10 ng/ml), and more time between the biopsy and the radical prostatectomy were significantly associated with a higher risk of upgrading. Positive margins and PSA relapse occurred more frequently in upgraded patients. Center size did not significantly affect the concordance rate (p = 0.40).This prospective, nationwide analysis demonstrated a Gleason score concordance rate of 62.9%. Upgrading was most frequently observed in the non-concordant group. We identified clinical and pathological factors associated with (non)-concordance. Upgrading was associated with a worse oncological outcome. Center volume was not associated with pathological accuracy.
Literatur
1.
Zurück zum Zitat Gleason DF (1966) Classification of prostate carcinomas. Cancer Chemother 50:125–128 Gleason DF (1966) Classification of prostate carcinomas. Cancer Chemother 50:125–128
2.
Zurück zum Zitat Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228–1242CrossRef Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228–1242CrossRef
3.
Zurück zum Zitat Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA (2014) The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40(2):244–252 Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA (2014) The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40(2):244–252
4.
Zurück zum Zitat Kvale R, Moller B, Wahiqvist R et al (2008) Concordance between Gleason score of needle biopsies and radical prostatectomy specimens: a population-based study. BJUI 103:1647–1654CrossRef Kvale R, Moller B, Wahiqvist R et al (2008) Concordance between Gleason score of needle biopsies and radical prostatectomy specimens: a population-based study. BJUI 103:1647–1654CrossRef
5.
Zurück zum Zitat Rapiti E, Schaffar R, Iselin C et al (2013) Importance and determinants of Gleason score undergrading on biopsy sample of prostate cancer in a population-based study. MBC Urol 13:19 Rapiti E, Schaffar R, Iselin C et al (2013) Importance and determinants of Gleason score undergrading on biopsy sample of prostate cancer in a population-based study. MBC Urol 13:19
6.
Zurück zum Zitat Müntener M, Epstein JI, Henandez DJ et al (2008) Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 53:767–776CrossRef Müntener M, Epstein JI, Henandez DJ et al (2008) Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 53:767–776CrossRef
7.
Zurück zum Zitat King CR (2000) Patterns of prostate cancer biopsy grading: trends and clinical implications. Int J Cancer 90:305–311CrossRef King CR (2000) Patterns of prostate cancer biopsy grading: trends and clinical implications. Int J Cancer 90:305–311CrossRef
8.
Zurück zum Zitat Isariyawongse BK, Sun L, Banez L et al (2008) Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. Urology 72:882–886CrossRef Isariyawongse BK, Sun L, Banez L et al (2008) Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. Urology 72:882–886CrossRef
9.
Zurück zum Zitat Joniau S, Spyrantis M, Birganti A et al (2018) Gleason score 6 prostate cancer is not always harmless. Eur Urol Suppl 17(2):e242–e243CrossRef Joniau S, Spyrantis M, Birganti A et al (2018) Gleason score 6 prostate cancer is not always harmless. Eur Urol Suppl 17(2):e242–e243CrossRef
10.
Zurück zum Zitat Albissini S, Joniau S, Quackels T et al (2017) Current trends in patient enrolment for robotic-assisted laparoscopic prostatectomy in Belgium. Cancer 123(21):4139–4146CrossRef Albissini S, Joniau S, Quackels T et al (2017) Current trends in patient enrolment for robotic-assisted laparoscopic prostatectomy in Belgium. Cancer 123(21):4139–4146CrossRef
12.
Zurück zum Zitat McHugh (2012) Interrater reliability: the kappa statistic. Biochem Med 22(3):276–282CrossRef McHugh (2012) Interrater reliability: the kappa statistic. Biochem Med 22(3):276–282CrossRef
13.
Zurück zum Zitat Wong AT, Agarwal M, Navo EB, Schwartz D, Schreiber D (2017) Concordance of gleason score on biopsy and after prostatectomy: a SEER databyse analysis. J Clin Oncol 33:50CrossRef Wong AT, Agarwal M, Navo EB, Schwartz D, Schreiber D (2017) Concordance of gleason score on biopsy and after prostatectomy: a SEER databyse analysis. J Clin Oncol 33:50CrossRef
14.
Zurück zum Zitat Evans SM, Bandarage VP, Kronborg C, Earnest A, Millar J, Clouston D (2016) Gleason group concordance between biopsy and radical prostatectomy specimen. A cohort study from prostate Cancer outcome registry – Victoria. Prostate Int 4:145–151CrossRef Evans SM, Bandarage VP, Kronborg C, Earnest A, Millar J, Clouston D (2016) Gleason group concordance between biopsy and radical prostatectomy specimen. A cohort study from prostate Cancer outcome registry – Victoria. Prostate Int 4:145–151CrossRef
15.
Zurück zum Zitat Cumming JA, Ritchie AWS, Goodman CM, McIntyre MA, Chisholm GF (1990) De-differentiation with time in prostate cancer and the influence of treatment on the course of the disease. BJI 65:271–274 Cumming JA, Ritchie AWS, Goodman CM, McIntyre MA, Chisholm GF (1990) De-differentiation with time in prostate cancer and the influence of treatment on the course of the disease. BJI 65:271–274
16.
Zurück zum Zitat Fossati N, Rossi MS, Cucchiara V et al (2017) Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely? Urol Oncol 35(4):150.e9–150.15CrossRef Fossati N, Rossi MS, Cucchiara V et al (2017) Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely? Urol Oncol 35(4):150.e9–150.15CrossRef
17.
Zurück zum Zitat Gupta N, Bivalacqua TJ, Han M, Gorin MA, Challacombe BJ, Partin AW, Mamawala MK (2019) Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to very-high-risk clinically localised prostate cancer. BJU Int 124:268–274CrossRef Gupta N, Bivalacqua TJ, Han M, Gorin MA, Challacombe BJ, Partin AW, Mamawala MK (2019) Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to very-high-risk clinically localised prostate cancer. BJU Int 124:268–274CrossRef
18.
Zurück zum Zitat Meunier ME, Neuzillet Y, Radulescu C, Cherbonnier C, Hervé JM, Rouanne M, Molinié V, Lebret T (2018) Does the delay from prostate biopsy to radical prostatectomy influence the risk of biochemical recurrence? Prog Urol 28(10):475–481CrossRef Meunier ME, Neuzillet Y, Radulescu C, Cherbonnier C, Hervé JM, Rouanne M, Molinié V, Lebret T (2018) Does the delay from prostate biopsy to radical prostatectomy influence the risk of biochemical recurrence? Prog Urol 28(10):475–481CrossRef
19.
Zurück zum Zitat Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Gillessen S, Bossi A, Roupret M, Powles T, Necchi A, Catto JWF, Klaassen Z (2020) Risks from deferring treatment for genitourinary cancers: a collaborative review to aid triage and management during the COVID-19 pandemic. Eur Urol 78:29–42CrossRef Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Gillessen S, Bossi A, Roupret M, Powles T, Necchi A, Catto JWF, Klaassen Z (2020) Risks from deferring treatment for genitourinary cancers: a collaborative review to aid triage and management during the COVID-19 pandemic. Eur Urol 78:29–42CrossRef
20.
Zurück zum Zitat Ahmed HU, Bosaily AE, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815–822CrossRef Ahmed HU, Bosaily AE, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815–822CrossRef
21.
Zurück zum Zitat Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM, PRECISION Study Group Collaborators (2018) MRI-targeted or standard biopsy for prostate-Cancer diagnosis. N Engl J Med 378(19):1767–1777CrossRef Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM, PRECISION Study Group Collaborators (2018) MRI-targeted or standard biopsy for prostate-Cancer diagnosis. N Engl J Med 378(19):1767–1777CrossRef
22.
Zurück zum Zitat Van Hove A, Savoie PH, Maurin C et al (2014) Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies. World J Urol 32:847–858CrossRef Van Hove A, Savoie PH, Maurin C et al (2014) Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies. World J Urol 32:847–858CrossRef
23.
Zurück zum Zitat Kayano PP, Carneiro K, Castilho TML et al (2018) Comparison of Gleason upgrading rates in transrectal ultrasound systematic random biopsies versus US-MRI fusion biopsies for prostate cancer. Int Braz J Urol 44(6):1106–1113CrossRef Kayano PP, Carneiro K, Castilho TML et al (2018) Comparison of Gleason upgrading rates in transrectal ultrasound systematic random biopsies versus US-MRI fusion biopsies for prostate cancer. Int Braz J Urol 44(6):1106–1113CrossRef
24.
Zurück zum Zitat Truesdale MD, Cheetham PJ, Turk AT et al (2010) Gleason score concordance on biopsy-confirmed prostate cancer: is pathological re-evaluation necessary prior to radical prostatectomy? BJU Int 107:749–754CrossRef Truesdale MD, Cheetham PJ, Turk AT et al (2010) Gleason score concordance on biopsy-confirmed prostate cancer: is pathological re-evaluation necessary prior to radical prostatectomy? BJU Int 107:749–754CrossRef
25.
Zurück zum Zitat Allsbrook WC, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI (2001) Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 32(1):81–88CrossRef Allsbrook WC, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI (2001) Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 32(1):81–88CrossRef
26.
Zurück zum Zitat Corcoran NM, Hong MK, Casey RG et al (2011) Upgrading in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int 108:202–210CrossRef Corcoran NM, Hong MK, Casey RG et al (2011) Upgrading in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int 108:202–210CrossRef
Metadaten
Titel
Concordance Between Biopsy and Radical Prostatectomy Gleason Scores: Evaluation of Determinants in a Large-Scale Study of Patients Undergoing RARP in Belgium
verfasst von
C. Soenens
P. Dekuyper
G. De Coster
N. Van Damme
E. Van Eycken
T. Quackels
T. Roumeguère
B. Van Cleynenbreugel
S. Joniau
F. Ameye
for the Be-RALP registry
Publikationsdatum
06.07.2020
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 4/2020
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-020-00860-w

Weitere Artikel der Ausgabe 4/2020

Pathology & Oncology Research 4/2020 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.